Previous 10 | Next 10 |
2023-03-30 18:39:41 ET Belgian biotech Galapagos NV ( NASDAQ: GLPG ) on Thursday said it would transfer its drug discovery and research activities in Romainville, France to contract research organization NovAliX. NovAliX will assume GLPG's research capabilities while...
Galapagos to transfer drug discovery and research activities in Romainville, France to NovAliX, a drug-discovery focused Contract Research Organization (CRO) based in Strasbourg, France NovAliX to assume Galapagos’ research capabilities, and Galapagos retains flexibility to access nece...
Publication of annual report for financial year 2022 Annual S hareholders ’ M eeting proposed resolutions include re - appointment of Board members and appointment of new statutory a uditor ...
2023-03-05 22:12:31 ET Summary David Einhorn's 13F stock portfolio value increased from $1.41B to $1.44B this quarter. Greenlight added Tenet Healthcare and increased Kyndryl Holdings, Southwestern Energy, and Global Payments during the quarter. The largest three positions are...
Six presentations demonstrate Galapagos’ commitment to the inflammatory bowel disease (IBD) community New analyses from Phase 3 SELECTION and SELECTION long-term extension (LTE) studies of Jyseleca ® (filgotinib, an oral, once daily, JAK1 preferential inhibitor) will be pres...
Galapagos NV (GLPG) Q4 2022 Earnings Conference Call February 24, 2023 08:00 AM ET Company Participants Sofie Van Gijsel - Senior Director of Investor Relations Paul Stoffels - Chief Executive Officer Bart Filius - Chief Operating Officer & President Daniele D&...
Galapagos press release ( NASDAQ: GLPG ): FY GAAP EPS of -€3.32 misses by €2.21 . Revenue of €505.3M (+4.2% Y/Y) misses by €77M . For FY 2023, co anticipates further reduction of its cash burn and anticipates landing between €380...
Key 202 2 and post - period events Dr. Paul Stoffels i appointed as Chief Executive Officer and Chairman of the Board of Directors Implemented new strategic direction to accelerate innovation and time-to-patients: Set-up of new innovation model and fit-for-pu...
Summary On February 8th, 2023, Galapagos announced disappointing results of their phase 3 DIVERSITY Crohn's disease study; the company is no longer planning to file an MAA. Galapagos stock fell 8%, and the stock is still hovering around negative $2.0Bn enterprise value territory. We...
All 7 out of 7 eligible patients with relapsed/refractory Chronic Lymphocytic Leukemia, with or without Richter’s transformation, responded to treatment (Objective Response Rate of 100%) GLPG5201 showed an acceptable safety profile with no cytokine release syndrome (CRS) higher than gr...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...